Visalytics
Visalytics
approved EB-2 (NIW)

Postdoctoral Researcher

Cancer Immunotherapy · Iran · 2025-04-19

Processing Time
126 days
Decision Date
2025-04-19
Location
Pennsylvania
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop synergistic combination therapies that merge genetic engineering of viruses and immune cells to transform cancer treatment. His work focuses on enhancing therapeutic precision while reducing toxicity, treatment costs, and overall patient burden for those with solid tumors. The endeavor aims to integrate engineered immune cells with viral vectors to achieve more efficient tumor targeting.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research addresses the urgent need for safer, cost-effective cancer treatments, aligning with national healthcare priorities.

2 Well-positioned to Advance the Endeavor Met

The petitioner's record of 18 publications and over 300 citations demonstrates his expertise and influence in the field.

3 On Balance, Beneficial to Waive Job Offer Met

The broader health and economic benefits of the petitioner's research justify waiving the labor certification requirement.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 18 peer-reviewed journal articles and 304 citations, demonstrating significant influence in the medical research community. The legal strategy successfully argued the national importance of his work in reducing healthcare costs and improving survival outcomes for cancer patients. USCIS found that the evidence satisfied all three prongs of the Dhanasar framework.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Conference Presentations
Original Contributions
Government Alignment

Similar Cases

Postdoctoral Researcher

Biotechnology · China

WeGreened EB-2 (NIW) approved
Pennsylvania 8 days 2025-02-05
The petitioner proposes to engineer immune cells and design tumor-targeting therapies using novel immunotherapy approaches, such as lentiviral systems. The work focuses on developing conditionally dependent peptides that target tumors with high precision to enhance treatment effectiveness. The goal is to create next-generation treatment strategies that reduce cancer relapse and minimize side effects for patients.
View Case

Others

Biotechnology · Iran

WeGreened EB-2 (NIW) approved
New Jersey 180 days 2025-09-03
The petitioner proposes to combine molecular biology methods with innovative drug delivery systems to enhance immune recognition of cancer cells. Her work focuses on developing next-generation immunotherapies that provide highly effective and less toxic treatment options for patients.
View Case

Postdoctoral Researcher

Biotechnology · Mexico

WeGreened EB-2 (NIW) approved
Maryland 489 days 2022-08-22
The petitioner proposes to develop a highly quantitative understanding of the interactions between cancer cells and the immune system. He utilizes high-resolution microscopy, high-throughput flow cytometry, and mathematical modeling to design personalized cancer immunotherapies that are more effective than current treatments.
View Case

Research Scientist

Biotechnology · Taiwan

WeGreened EB-2 (NIW) approved
Oklahoma 33 days 2025-09-10
The petitioner proposes to develop advanced preclinical cancer models to evaluate the efficacy and immune responses of novel immunotherapies, including cancer vaccines and antibody-drug conjugates. This work focuses on optimizing rational combination strategies to improve clinical outcomes for patients with treatment-resistant and aggressive cancers. The endeavor aims to bridge the gap between laboratory discovery and clinical application to make therapies safer and more accessible.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Biotechnology cases More cases from Iran

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-04-19.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 126 days
Criteria Met 3 / 3
Evidence Types 5

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Iran All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist